Clinical trials: Cancer-Associated Pain
Intractable Pain, Neoplasms
NP2 Enkephalin For Treatment of Intractable Cancer Pain
The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease.
- Trial name
- NCT01291901
- Testing
- NP2
- Where
- 18 sites in United States
- Volunteers
- 33 people
- Sponsor
- Diamyd Inc
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid (morphine-like medications) analgesics (drug used to…
- Trial name
- NCT01309386
- Testing
- Tapentadol ER, Morphine SR
- Where
- 22 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Janssen Pharmaceutical K.K.
Moderate-to-severe Chronic Noncancer Pain
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
- Trial name
- NCT02603705
- Testing
- Oxycodone extended-release
- Where
- 39 sites in United States
- Volunteers
- 281 people
- Sponsor
- Egalet Ltd
Fibrocystic Disease of Breast, Fibrocystic Changes of Breast
Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain
History of clinical breast pain for at least the last six months. At least six days of moderate or severe breast pain per cycle. Fibrosis, cysts, nodules involving at least 25% of the surface of one breast.
- Conditions
- Fibrocystic Disease of Breast, Fibrocystic Changes of Breast, Fibrocystic Mastopathy, Pain
- Trial name
- NCT00237523
- Testing
- IoGen (molecular iodine)
- Where
- 39 sites in United States
- Volunteers
- 175 people
- Sponsor
- Symbollon Pharmaceuticals
Uterine Fibroids
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.
- Trial name
- NCT02655224
- Testing
- Relugolix
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Takeda
Moderate to Severe Chronic Non-cancer Pain
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain
The purpose of this study is to evaluate the safety and effectiveness of prolonged release tapentadol hydrochloride for the relief of moderate to severe chronic non-cancer pain among Filipino patients.
- Trial name
- NCT01719588
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
Opioid-Induced Constipation
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
This purpose of this study is to evaluate the safety and effectiveness of a subcutaneous (injection beneath the skin) form of methylnaltrexone in subjects who have cancer-related pain and constipation from taking opioids.
- Trial name
- NCT00858754
- Testing
- methylnaltrexone
- Where
- 8 sites in United States, Canada and 2 more
- Sponsor
- Bausch Health Americas, Inc.
Pain, Burning, Pain, Crushing
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
The purpose of this study is to compare the safety and effectiveness of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.
- Conditions
- Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating
- Trial name
- NCT00929188
- Testing
- JNJ-42160443
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Nausea Post Chemotherapy, Vomiting
Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC
Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic…
- Conditions
- Nausea Post Chemotherapy, Vomiting, Cancer Pain, Cancer Related Pain
- Trial name
- NCT05272865
- Testing
- Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
- Where
- Colombia
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- LaSanta S A S
Cancer, Pain
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
- Trial name
- NCT01885182
- Testing
- Oxycodone/Naloxone, Oxycodone
- Where
- 28 sites in China
- Volunteers
- 232 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Cancer, Pain
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
This study is to evaluate the efficacy and safety of a titration method by selects 10 mg control-released (CR) oxycodone tablet as background drug in combined with immediate-released (IR) oxycodone, compared to conventional…
- Trial name
- NCT03176199
- Testing
- Oxycodone
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Cancer, Chronic Pain
Tapentadol in Chronic Malignant Tumour Related Pain
The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain.
- Conditions
- Cancer, Chronic Pain, Pain
- Trial name
- NCT01264887
- Testing
- Tapentadol Prolonged Release
- Where
- 12 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 31 people
- Sponsor
- Grünenthal GmbH
Acute Ankle Sprain
Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain
This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or…
- Trial name
- NCT01874626
- Testing
- SST-0225 Topical Ibuprofen Cream
- Where
- United States
- Volunteers
- 305 people
- Sponsor
- Strategic Science & Technologies, LLC
Pain, Analgesics, Opioid
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain…
- Trial name
- NCT00410878
- Testing
- OROS Hydromorphone HCI (slow release)
- Volunteers
- 22 people
- Sponsor
- Alza Corporation, DE, USA
Chronic Pain
Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain
The purpose of this study is to confirm effectiveness and safety of fentanyl transdermal patch Durogesic® D-Trans for treatment of chronic pain in participants with chronic non-cancer pain.
- Trial name
- NCT01902524
- Testing
- Fentanyl-TTS
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pain, Advanced Cancer
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
This 9-week study aimed to determine the efficacy, safety, and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with…
- Trial name
- SPRAY III (NCT01361607)
- Testing
- Nabiximols
- Where
- 68 sites in United States, Bulgaria and 8 more
- Volunteers
- 399 people
- Sponsor
- Jazz Pharmaceuticals
Cancer Pain
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
- Trial name
- NCT05265052
- Testing
- 3D1002 (50 mg)(Phase IIa), 3D1002 (100 mg)(Phase IIa), 3D1002 (150 mg)(Phase IIa)
- Volunteers
- 177 people
- Sponsor
- 3D Medicines
Cancer, Pain
Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain
M40403 was found to be effective in reducing pain in animal models and in clinical studies of subjects who were experiencing pain after dental surgery.
- Trial name
- NCT00101621
- Testing
- M40403
- Volunteers
- 24 people
- Sponsor
- MetaPhore Pharmaceuticals
Pain, Cancer
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
The purpose of this study is to evaluate the efficacy and safety of fentanyl 1-day application (JNS020QD) transdermal patch (patch containing a drug that is put on the skin so the drug can enter the body through the skin) and to…
- Trial name
- NCT00644787
- Testing
- Fentanyl 1-day transdermal patch (Titration Phase), Fentanyl 1-day transdermal patch (Double Blind Phase), Fentanyl 3-day transdermal patch (Double Blind Phase)
- Where
- 43 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Janssen Pharmaceutical K.K.